Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Rhea-AI Summary

Renovacor, a biotechnology company trading as RCOR, announced that its analytical and biophysical assay results for REN-001 will be showcased at the 29th European Society of Gene & Cell Therapy Congress from October 11-14, 2022, in Edinburgh, Scotland. REN-001 targets BAG3-associated dilated cardiomyopathy, a serious heart condition. The poster presentation, led by Dr. Angela Mohs, is scheduled for October 14, 2022, from 5:30-7:15 p.m. British Summer Time.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company’s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentation at the 29^th European Society of Gene & Cell Therapy (ESGCT) Congress. The congress is taking place from October 11 – 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.

REN-001 is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure. The upcoming poster (P046), titled, “Analytical and biophysical characterization of a rAAV9 vector for in-vivo gene therapy to treat dilated cardiomyopathy,” will be presented from 5:30 – 7:15 p.m. British Summer Time on October 14, 2022. The poster’s presenting author is Angela Mohs, Ph.D., Director of Analytical Development at Renovacor.

About Renovacor
Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are based upon current estimates and assumptions of the Company and its management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, the ability of the company to grow and manage growth, maintain relationships with customers and suppliers and retain its management and key employees; the Company's ability to successfully advance its current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the Company’s ability to submit an IND related to REN-001 on its anticipated timeline, and any challenges related to the clearance of such IND by the FDA; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business or competitive factors, including inflationary pressures; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; the ability of the Company to defend its intellectual property; the impact of the COVID-19 pandemic on the Company’s business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of the Company's annual and quarterly and reports filed the Securities Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Renovacor gives no assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005557/en/

Brooks Rahmer

Renovacor, Inc.

610-424-2627

ir@renovacor.com

Source: Renovacor, Inc.

FAQ

What is REN-001 by Renovacor?

REN-001 is an AAV-based gene therapy developed by Renovacor, targeting BAG3-associated dilated cardiomyopathy.

When will Renovacor present at the ESGCT Congress?

Renovacor will present a poster on REN-001 at the ESGCT Congress on October 14, 2022, from 5:30-7:15 p.m.

Where is the 29th ESGCT Congress being held?

The 29th ESGCT Congress is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland.

Who is presenting the poster on REN-001?

Dr. Angela Mohs, Director of Analytical Development at Renovacor, will present the poster for REN-001.

What is the significance of the ESGCT Congress for Renovacor?

The ESGCT Congress is significant for Renovacor as it allows them to showcase critical assay results for their gene therapy REN-001.